Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Surgical Oncology

Background: The primary treatment for locally advanced epithelial ovarian cancer is still confusing. Cytoreductive surgery is the cornerstone of treatment for epithelial ovarian cancer with an inverse relation between residual volume and expected survival. Aim: The aim of this study was to study the impact of primary debulking surgery in women with locally advanced epithelial ovarian cancer versus neoadjuvant chemotherapy and interval debulking surgery. Methods: All patients with locally advanced epithelial ovarian cancer attending at National Cancer Institute, Cairo University dating from September 2016 till the end of January 2018 were included in that trial. Results: A total number of 57 patients with primary epithelial ovarian cancer were treated and followed up during the period of the study. Primary Debulking Surgery (PDS) was done for 20 cases that represent group A, while NeoAdjuvant ChemoTherapy (NACT) and Interval Debulking Surgery (IDS) was done for 37 cases that represent group B. The median age of group A was 54.5 years while it was 56 years for group B. The median level of CA125 level for group A was 574 and 600 for group B Surgery was done in 57patients and he median peritoneal carcinomatosis index (PCI)) for group A was 9 while it was 7 for group B. The median hospital stay was 6 days. Sixteen patients had postoperative complications, 6(30%) of them were from group A while 10(27%) patients were from group B. The median follow up time in the studied group was 22 months ranging from 1 month to 34 months

Issued also as CD